Search alternatives:
we decrease » _ decrease (Expand Search), teer decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 701 - 720 results of 227,223 for search '(( 5 ((we decrease) OR (mean decrease)) ) OR ( 10 ((nn decrease) OR (a decrease)) ))', query time: 1.89s Refine Results
  1. 701
    Tim-3 deficiency enhances the levels of proinflammatory cytokines and decreases the parasite burden.

    Tim-3 deficiency enhances the levels of proinflammatory cytokines and decreases the parasite burden. by Houbao Qi (11996039)

    Published 2023
    Save to List
    Saved in:
  2. 702
    Antitumor Activity of FGFR Inhibitor as a Result of a Decrease in the Breast TIC Subpopulation In Vivo.

    Antitumor Activity of FGFR Inhibitor as a Result of a Decrease in the Breast TIC Subpopulation In Vivo. by Sungeun Kim (105743)

    Published 2013
    Save to List
    Saved in:
  3. 703
    TH588 effectively decreases cellular survival in heterogeneous neuroendocrine tumor cells.

    TH588 effectively decreases cellular survival in heterogeneous neuroendocrine tumor cells. by Elke Tatjana Aristizabal Prada (833927)

    Published 2017
    Save to List
    Saved in:
  4. 704
    CXCL10 production is enhanced in the setting of HIV and HBV co-infection in vitro and decreased with the addition of antiretroviral agents efavirenz or raltegravir.

    CXCL10 production is enhanced in the setting of HIV and HBV co-infection in vitro and decreased with the addition of antiretroviral agents efavirenz or raltegravir. by Kasha P. Singh (9354307)

    Published 2020
    Save to List
    Saved in:
  5. 705
    The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages.

    The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

    Published 2013
    Save to List
    Saved in:
  6. 706
    Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism.

    Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism. by Bolin Liu (59887)

    Published 2009
    Save to List
    Saved in:
  7. 707
    A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner.

    A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

    Published 2016
    Save to List
    Saved in:
  8. 708
    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells.

    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

    Published 2014
    Save to List
    Saved in:
  9. 709
    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells.

    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

    Published 2014
    Save to List
    Saved in:
  10. 710
    Resveratrol decreases CYP17A1 and CYP21A2 protein expression.

    Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

    Published 2017
    “…Data are the mean ± SD of three independent SYBR Green based qRT-PCR experiments. …”
    Save to List
    Saved in:
  11. 711
    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells.

    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

    Published 2013
    Save to List
    Saved in:
  12. 712
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 713
    CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i><sup><i>ECKO</i></sup> mice and lesions in the retina of <i>Ccm2</i><sup><i>ECKO</i></sup> mice.

    CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i><sup><i>ECKO</i></sup> mice and lesions in the retina of <i>Ccm2</i><sup><i>ECKO</i></sup> mice. by Jia Li (160557)

    Published 2020
    Save to List
    Saved in:
  14. 714
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 715
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 716
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 717
    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease

    Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease by Christine M. LaPash Daniels (796881)

    Published 2015
    “…Here we tested whether lithium treatment would decrease levels of GFAP in a mouse model of Alexander disease. …”
    Save to List
    Saved in:
  18. 718
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 719
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 720
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: